A Randomized Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab+Docetaxel to Dostarlimab+Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (Costar Lung) | NYU Langone Health

Go Back to All Clinical Trials

A Randomized Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab+Docetaxel to Dostarlimab+Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (Costar Lung)